Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q1 2026 · 10-Q
Revenue$1.44M$1.44M−33.5% vs Q1 2025 Net Income-$189.84M-$189.84MN/M vs Q1 2025 EPS Diluted-$0.26-$0.26N/M vs Q1 2025 Operating Income-$365,993,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
Free Cash Flowderived-$270,923,000N/M Margins · derivedOperating margin-25380.9%−12250.9 pt vs Q1 2025
Net margin-13164.8%−2872.0 pt vs Q1 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end